Irving, Texas-based McKesson Corporation (MCK) provides healthcare services in the United States and internationally. With a market cap of $89.4 billion, McKesson operates through the U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International segments.

Companies worth $10 billion or more are generally referred to as “large-cap stocks.” MCK fits the bill perfectly, showcasing its substantial size, influence and dominance in the healthcare sector. MCK’s offerings include supply chain management solutions, community oncology and specialty care, healthcare IT solutions and more.

McKesson recently touched its all-time high of $731 on May 20 and is currently trading 2.9% below that peak. Over the past three months alone, MCK stock has soared 10.2%, outpacing the Health Care Select Sector SPDR Fund’s (XLV) 10.1% plunge during the same time frame.

McKesson’s performance looks even more impressive over the longer term. MCK stock has surged 24.5% on a YTD basis and 23.7% over the past year, significantly outperforming XLV’s 3.1% dip in 2025 and 8.2% decline over the past 52 weeks.

MCK stock has remained consistently above its 200-day moving average since early November 2024 and has been mostly above its 50-day moving average since late January, with some fluctuations, underscoring its bullish trend.

McKesson’s stock prices observed a marginal uptick in the trading session after the release of its mixed Q4 results on May 8. Driven by the strength of its pharma distribution division, expansion of oncology platform, and continued growth in biopharma solutions, MCK’s overall topline soared 18.9% year-over-year to $90.8 billion. However, this figure fell short of Street’s expectations. Meanwhile, driven by solid margin expansion and share buyback, MCK’s adjusted EPS for the quarter increased by an even more impressive 63.8% year-over-year to $10.12, exceeding the consensus estimates by 3.2%.

Furthermore, the company’s operating cash flows for the full fiscal 2025 ended on Mar. 31 surged 41.1% year-over-year to $6.1 billion.

Despite its solid performance, McKesson has slightly underperformed its peer Cencora, Inc.’s (COR) 28.6% surge on a YTD basis and 25.3% returns over the past 52 weeks.

Among the 17 analysts covering the MCK stock, the consensus rating is a “Strong Buy.” Its mean price target of $760.94 suggests a notable 7.3% upside potential from current price levels.